TP53 and acute myeloid leukemia: Additionally, the dnMAML (a pan-Notch inhibitor) could not affect AML proliferation in vitro but lead to dramatic increases in leukemia burden in two xenograft mouse models, which was associated with p53 dysregulation [45].